be obtained by writing the Freedom of Information Staff (address above). The request should identify by the NDA number the EA's and FONSI's requested. Separate requests should be submitted for each NDA. For additional information regarding the submission of freedom of information requests call 301–443–6310.

Dated: September 13, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–24149 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96G–0324]

Roquette America, Inc., and American Maize-Products Co.; Filing of a Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Roquette America, Inc., and American Maize-Products Co. have filed a petition (GRASP 6G0421) proposing to affirm that beta-cyclodextrin is generally recognized as safe (GRAS) as a flavor protectant in human food.

DATES: Written comments by December 4, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mitchell A. Cheeseman, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3083.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (secs. 201(s) and 409(b)(5) (21 U.S.C. 321(s) and 348(b)(5)), and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that Roquette America, Inc., and American Maize-Products Co., c/o Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001, have filed a petition (GRASP 6G0421) proposing to affirm that beta-cyclodextrin is GRAS as a flavor protectant in human food.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in §§ 170.30 (21 CFR 170.30) and 170.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Interested persons may, on or before December 4, 1996, review the petition and file comments with the Dockets Management Branch (address above). Two copies of any comments should be filed and should be identified with the docket number found in brackets in the heading of this document. Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. In addition, consistent with the regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency encourages public participation by review of and comment on the environmental assessment submitted with the petition that is the subject of this notice. A copy of the petition (including the environmental assessment) and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 14, 1996.

Eugene C. Coleman,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–24148 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee Meeting; Postponement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Antiviral Drugs Advisory Committee scheduled for September 26 and 27, 1996. The meeting was announced by a notice in the Federal Register of September 4, 1996 (61 FR 46652). This meeting is being postponed to allow time to incorporate the results of additional study information which have recently become available for the new drug application 20–705, delavirdine (Rescriptor®, Pharmacia and Upjohn Co.) for use in the treatment of human immunodeficiency virus (HIV) infection. The meeting will be rescheduled at a later date and will be announced in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Rhonda W. Stover, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455; or call the FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Antiviral Drugs Advisory Committee, code 12531.

Dated: September 13, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–24147 Filed 9–19–96; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

Submission for OMB Review; Comment Request; Agricultural Health Study—A Prospective Cohort Study of Cancer and Other Diseases Among Men and Women in Agriculture

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on June 13, 1996 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented after 10/1/95, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: Title: Agricultural Health Study—A Prospective Cohort Study of Cancer and Other Diseases Among Men and Women in Agriculture. Type of Information Collection Request: Revision (0925–0406, expiration 8/13/96). Need and Use of Information Collection: The Agricultural Health Study is in its third year of data collection on a prospective cohort of 75,000 farmers, their spouses, and commercial applicators of pesticides from Iowa and North